Cargando…
Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?
Despite significant advances in disease modifying therapy in heart failure (HF), diuretics have remained the cornerstone of volume management in all HF phenotypes. Diuretics, alongside their definite acute haemodynamic and symptomatic benefits, also possess many possible deleterious side effects. Mo...
Autores principales: | Kerr, Brian, Pharithi, Rebabonye B, Barrett, Matthew, Halley, Carmel, Gallagher, Joe, Ledwidge, Mark, McDonald, Kenneth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Heart Failure
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536695/ https://www.ncbi.nlm.nih.gov/pubmed/36262879 http://dx.doi.org/10.36628/ijhf.2020.0043 |
Ejemplares similares
-
Neprilysin in HFrEF: Differential Regulation of Tissue Versus Circulating Neprilysin
por: Chen, Horng H., et al.
Publicado: (2020) -
Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF
por: Prausmüller, Suriya, et al.
Publicado: (2020) -
Changing to remote management of a community heart failure population during COVID-19 – Clinician and patient perspectives’
por: Kerr, Brian, et al.
Publicado: (2020) -
Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
por: Grossekettler, Leonie, et al.
Publicado: (2020) -
Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023)